Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial - Concepedia

Concepedia

Publication | Closed Access

Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial

476

Citations

25

References

2014

Year

Helmut Oettle, Hanno Riess, Jens Stieler, Gerhard Heil, Ingo Schwaner, Jörg Seraphin, Martin Görner, Matthias Mölle, Tim F. Greten, Volker Lakner,

Journal of Clinical Oncology

Abstract

Second-line OFF significantly extended the duration of overall survival when compared with FF alone in patients with advanced gemcitabine-refractory pancreatic cancer.

References

	Year	Citations
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer Thierry Conroy, Françoise Desseigne, Marc Ychou, New England Journal of Medicine	2011	7.6K
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Daniel D. Von Hoff, Thomas J. Ervin, Francis P. Arena, New England Journal of Medicine	2013	6.5K
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Howard A. Burris, Malcolm J. Moore, John Sahl Andersen, Journal of Clinical Oncology	1997	5.8K
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Malcolm J. Moore, David Goldstein, John Hamm, Journal of Clinical Oncology	2007	3.8K
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group Uwe Pelzer, Ingo Schwaner, Jens Stieler, European Journal of Cancer OncologyPancreatic CancerGastrointestinal OncologyCancer ManagementPhase Iii-study	2011	379
Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer Brian M. Wolpin, Aram F. Hezel, Thomas A. Abrams, Journal of Clinical Oncology	2008	291
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy G. Bodoky, Constanta Timcheva, David R. Spigel, Investigational New Drugs Phase Ii Open-labelUrologyPancreatic CancerGastrointestinal OncologyMedicine	2011	228
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer Changhoon Yoo, Jenn-Jiang Hwang, Je Hyeong Kim, British Journal of Cancer	2009	169
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer Matthew H. Kulke, Lawrence S. Blaszkowsky, David P. Ryan, Journal of Clinical Oncology	2007	166
Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer Henry Q. Xiong, Gauri R. Varadhachary, J. C. Blais, Cancer	2008	141

Page 1